Dataset Information

TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel Testing.

ABSTRACT: Assessment of age-dependent cancer risk for carriers of a predicted pathogenic variant (PPV) is often hampered by biases in data collection, with a frequent under-representation of cancer-free PPV carriers. TUMOSPEC was designed to estimate the cumulative risk of cancer for carriers of a PPV in a gene that is usually tested in a hereditary breast and ovarian cancer context. Index cases are enrolled consecutively among patients who undergo genetic testing as part of their care plan in France. First- and second-degree relatives and cousins of PPV carriers are invited to participate whether they are affected by cancer or not, and genotyped for the familial PPV. Clinical, family and epidemiological data are collected, and all data including sequencing data are centralized at the coordinating centre. The three-year feasibility study included 4431 prospective index cases, with 19.1% of them carrying a PPV. When invited by the coordinating centre, 65.3% of the relatives of index cases (5.7 relatives per family, on average) accepted the invitation to participate. The study logistics were well adapted to clinical and laboratory constraints, and collaboration between partners (clinicians, biologists, coordinating centre and participants) was smooth. Hence, TUMOSPEC is being pursued, with the aim of optimizing clinical management guidelines specific to each gene.

SUBMITTER: Lesueur F

PROVIDER: S-EPMC8345200 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel Testing.

Lesueur Fabienne F Eon-Marchais Séverine S Bonnet-Boissinot Sarah S Beauvallet Juana J Dondon Marie-Gabrielle MG Golmard Lisa L Rouleau Etienne E Garrec Céline C Martinez Mathilde M Toulas Christine C Nguyen Tan Dat TD Brayotel Fanny F Crivelli Louise L Maugard Christine M CM Bubien Virginie V Sevenet Nicolas N Gesta Paul P Chieze-Valero Stéphanie S Nambot Sophie S Goussot Vincent V Mari Véronique V Popovici Cornel C Prieur Fabienne F Morin-Meschin Marie-Emmanuelle ME Tinat Julie J Lortholary Alain A Dreyfus Hélène H Bidart Marie M Collonge-Rame Marie-Agnès MA Mozelle-Nivoix Monique M Gladieff Laurence L Giraud Sophie S Boutry-Kryza Nadia N Chiesa Jean J Denizeau Philippe P Bignon Yves-Jean YJ Uhrhammer Nancy N Cohen-Haguenauer Odile O Vilquin Paul P Mailliez Audrey A Coupier Isabelle I Rey Jean-Marc JM Lacaze Elodie E Béra Odile O Colas Chrystelle C Coulet Florence F Delnatte Capucine C Houdayer Claude C Lasset Christine C Lemonnier Jérôme J Longy Michel M Noguès Catherine C Stoppa-Lyonnet Dominique D Vaur Dominique D Andrieu Nadine N Caron Olivier O

Cancers 20210721 15

Assessment of age-dependent cancer risk for carriers of a predicted pathogenic variant (PPV) is often hampered by biases in data collection, with a frequent under-representation of cancer-free PPV carriers. TUMOSPEC was designed to estimate the cumulative risk of cancer for carriers of a PPV in a gene that is usually tested in a hereditary breast and ovarian cancer context. Index cases are enrolled consecutively among patients who undergo genetic testing as part of their care plan in France. Fir ...[more]

PMID: 34359559

Similar Datasets

Project description:Background. Expansion of routine genetic testing for hereditary breast and ovarian cancer from conventional BRCA testing to a multigene test could improve diagnostic yield and increase the opportunity for cancer prevention in both identified carriers and their relatives. We use an economic decision model to assess whether the current knowledge on non-BRCA mutation prevalence, cancer risk, and patient preferences justifies switching to a multigene panel for testing of early-onset breast cancer patients. Methods. We evaluated routine testing by BRCA testing, a 7-gene panel, and a 14-gene panel using individual-level simulations of annual health state transitions over a lifetime perspective. Breast and ovarian cancer incidence is reduced and posttreatment survival is improved when high-risk mutations are detected and risk-reducing treatment offered. Most model inputs were synthesized from published literature. Intermediate health outcomes included breast and ovarian cancer incidence rates, along with organ-specific cancer mortality. Cost-effectiveness outcomes were health sector costs and quality-adjusted life years. Results. Intermediate health outcomes improved by testing with multigene panels. At a cost-effectiveness threshold of $77,000, a 7-gene panel test with five non-BRCA genes was the optimal strategy with an incremental cost-effectiveness ratio of $53,310 per quality-adjusted life year compared to BRCA-only testing. Limitations. Unable to stratify carriers to specific mutations within genes, we can only make predictions on the gene level, with combined risk estimates for known variants. As mutation prevalence is the absolute upper bound of returns to more expansive testing, the rarity of modelled mutations makes analysis outcomes sensitive to model implementation. Conclusions. A 7-gene panel to diagnose hereditary breast and ovarian cancer in early-onset breast cancer patients can be a cost-effective alternative to current BRCA-only testing in Norway.

Dataset Information

TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel Testing.

Publications

TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel Testing.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets